MENU

Fox Chase Cancer Center News

Pramod Krishnamurthy, MD, MPH
November 12, 2012

Pramod Krishnamurthy, MD, MPH, Joins Fox Chase Cancer Center’s Department of Medicine

PHILADELPHIA, PA (November 12, 2012)—Pramod Krishnamurthy, MD, MPH, has joined Fox Chase Cancer Cancer’s pulmonary division within the department of medicine after completing a fellowship in interventional pulmonology at Henry Ford Hospital in Detroit, Mich. He has special interests in interventional pulmonology and its application in the diagnosis, staging, and treatment of lung and other cancers of the chest.

Larry Kaiser, MD, FACS
November 8, 2012

Temple’s Larry Kaiser, MD, FACS, Named a 'CEO of the Year'

(Philadelphia, PA, November 8, 2012) – Larry Kaiser, MD, FACS, President and CEO of the Temple University Health System, has been named a “CEO of the Year” at the 2012 Healthcare Innovation Awards, sponsored by the Philadelphia Business Journal. Dr. Kaiser was among three area healthcare CEOs who accepted their awards at a breakfast ceremony on Thursday, November 8, at the Sheraton Hotel in Philadelphia, PA.  

November 5, 2012

Fox Chase Holds FREE Event for Lung Cancer Patients

PHILADELPHIA (November 5, 2012)—Fox Chase Cancer Center invites lung cancer patients and their caregivers to a FREE event titled “Together Facing Lung Cancer” on Monday, November 12, 2012 at 5:00 p.m. (dinner will be served at 5:00 p.m. and official program will start at 5:45 p.m.). The event, which offers support to patients and caregivers facing lung cancer, will be held in the Fox Chase Cancer Center auditorium (333 Cottman Avenue, Philadelphia).

Joshua Meyer, MD
November 1, 2012

Fox Chase First in Region to Offer Newly FDA Approved Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases

PHILADELPHIA, PA (November 1, 2012)— Fox Chase Cancer Center is the first center in Pennsylvania to offer the newly U.S. Food and Drug Administration (FDA) approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.  

October 31, 2012

Routine Blood Test Predicts Prognosis in Aggressive Skin Cancer

BOSTON, MA (October 31, 2012)—A routine blood test may help predict survival in patients with an aggressive form of skin cancer known as Merkel cell carcinoma, according to new findings by Fox Chase Cancer Center researchers. The results will be presented on Wednesday, October 31 at the American Society for Radiation Oncology’s 54th Annual Meeting.

Joshua Meyer, MD
October 28, 2012

Age Tied to Spread of Rectal Cancer to Lymph Nodes

BOSTON, MA (October 28, 2012)—Rectal cancer is more likely to spread to the lymph nodes in younger patients, according to new findings that Fox Chase Cancer Center researchers will be presenting on October 29 at the American Society for Radiation Oncology’s 54th Annual Meeting. The results—which are the first of their kind—suggest that doctors should search for spreading more aggressively in these patients.

Tiffany Tam, MD
October 28, 2012

Fox Chase Researchers Connect Multifocal/Multicentric Breast Cancer to a Patient's Increased Risk of Local Recurrence

BOSTON, MA (October 28, 2012)—Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy.

October 28, 2012

Drop in Testosterone Tied to Prostate Cancer Recurrence

BOSTON, MA (October 28, 2012)—Men whose testosterone drops following radiation therapy for prostate cancer are more likely to experience a change in PSA levels that signals their cancer has returned, according to new research from Fox Chase Cancer Center. The findings will be presented on October 29 at the American Society for Radiation Oncology’s 54th Annual Meeting.

Specifically, men whose testosterone fell following various forms of radiation therapy were more likely to experience an increase in prostate-specific antigen (PSA)—often the first indication the cancer has recurred.

Pages

Connect with Fox Chase